Early-stage Immuno Rise Therapeutics is a small-to-mid biotech focused on first-in-class immune modulatory biologics with an oral delivery platform, presenting opportunities to position strategic partnerships or licensing deals with larger pharma seeking novel oral immunotherapies for inflammation, autoimmunity, and cancer.

NIH and TEDCO Support Recent NIH and TEDCO funding rounds underscore validation and subsequent credibility for funding partnerships, collaborations, and grant-based co-development opportunities that can be leveraged to de-risk co-investments or milestone-driven collaborations.

Robust Pipeline A developing portfolio around R-3750 for inflammatory bowel disease and broader oral immunotherapies indicates multiple entry points for collaboration, joint ventures, or co-development with therapeutic area specialists and contract research organizations.

Academic and NIH Links Active partnerships with University of Florida, Lastinger Center for Learning, and NIH indicate strong academic and government collaboration potential for research alliances, sponsored trials, and access to patient cohorts or translational research channels.

Commercial Readiness Gap With revenue in the low tens of millions and modest external funding, there is an opportunity to target strategic buyers or investors for later-stage partnerships, while offering services such as manufacturing scale-up consulting, regulatory strategy, or clinical development planning to accelerate growth.